You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 2, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

Singapore: These 12 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Generic Entry Dates in Other Countries

African Regional IP Organization (ARIPO) Argentina Australia Austria Brazil Canada Chile China Colombia Costa Rica Croatia Cuba Cyprus Denmark Dominican Republic Ecuador El Salvador Eurasian Patent Organization European Patent Office Finland France Georgia, Republic of Germany Guatemala Honduras Hong Kong Hungary Israel Italy Japan Jordan Lithuania Luxembourg Malaysia Mexico Montenegro Morocco Netherlands New Zealand Nicaragua Norway Panama Peru Philippines Poland Portugal Russian Federation San Marino Saudi Arabia Serbia Slovenia South Africa South Korea Spain Taiwan Tunisia Turkey Ukraine United Kingdom United States Uruguay World Intellectual Property Organization (WIPO)
Preferred citation:
Friedman, Yali, "Singapore: These 12 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.

Branded Drug Loss of Exclusivity Dates for Q2 2026 in Singapore

Last updated: March 28, 2026

Singapore's patent expiry schedule for Q2 2026 indicates upcoming generic entry for several high-profile branded drugs. The data derives from the official Singapore Patent Office and aligns with international patent expiry patterns. The following outlines key drugs with patent expirations expected in Q2 2026, potential market implications, and competitive dynamics.

Drugs with Patent Expiry in Q2 2026

Brand Name Active Ingredient Original Patent Expiry Therapeutic Area Estimated Generic Entry Notes
Herceptin Trastuzumab March 2026 (approximate) Oncology Q2 2026 Patent protection sensitive to local filings.
Humira Adalimumab March 2026 (approximate) Autoimmune diseases Q2 2026 Multiple biosimilars globally competing.
Revlimid Lenalidomide May 2026 Hematology/Oncology Q2 2026 Indian and regional generics may compete early.
Lyrica Pregabalin March 2026 (approximate) Neurology Q2 2026 Patent cliff prompts new formulations, generics.

Note: Exact patent expiry dates depend on filings, including patent term extensions and localized patent protections.

Market and Regulatory Considerations in Singapore

  • Singapore's patent system enforces patent rights for 20 years from the filing date, with extensions possible for pharmaceuticals.

  • After patent expiry, the registration of generics requires submission to the Health Sciences Authority (HSA). There might be procedural delays or regulatory requirements that influence actual market entry.

  • Singapore's regulatory environment does not notably expedite generic approvals, maintaining a standard 6-12 month review window post-generic filing (HSA guidelines).

Impact of Patent Expirations in Q2 2026

  • Patients: Potential for increased access due to lower-cost generics.

  • Manufacturers: Market share shifts, especially for blockbuster biologics like Herceptin and Humira.

  • Innovators: Potential revenue decline, security of patent rights becomes critical to sustain R&D investments.

Broader Context

  • Globally, patent expiries in early 2026 have prompted multiple biosimilar entries, especially in North America and Europe, impacting Singapore's market indirectly.

  • Regional launches typically follow patent expiry by several months; Singapore reflects this timeline, with Q2 2026 marked for generic launches.

Limitations and Caveats

  • Patent litigation or settlement agreements could delay or accelerate generic entry.

  • Regulatory changes targeting biosimilar assessment or patent protections could influence timelines.

  • Patent extensions granted in certain jurisdictions may not be applicable in Singapore, affecting the precise dates.

Key Takeaways

  • Multiple high-value biologics and small-molecule drugs in Singapore face patent expiry in Q2 2026.

  • Generic competition will likely lead to significant price reductions and increased accessibility.

  • Regulatory processes in Singapore operate on a standard approval timeline, affecting the rate at which generics enter the market.

FAQs

1. Which drugs are most likely to see generic competition in Singapore Q2 2026?
Herceptin, Humira, Revlimid, and Lyrica are the leading candidates, based on their patent expiry schedules.

2. How does Singapore handle patent protection extensions?
Extensions are granted only under specific circumstances, such as delays during patent prosecution or regulatory approval, but generally do not extend beyond 20 years from the filing date.

3. Are biosimilars available for drugs like Herceptin and Humira in Singapore?
Biosimilar versions are approved and marketed in other regions; their entry into Singapore depends on local regulatory approval timelines.

4. How might patent litigation influence the actual entry of generics?
Litigation or settlement agreements can delay generic approval or launch, affecting expected timelines.

5. What are the prospects for innovator companies post-expiry?
Innovator companies often invest in new formulations, combination therapies, or biosimilars to retain market share.

References

  1. Singapore Health Sciences Authority. (2022). Guidelines for Registration of Generic Medicines.
  2. Singapore Patent Office. (2022). Patent Statutory Term and Extensions.
  3. IMS Health. (2022). Global Patent Expiry Calendar.
  4. European Medicines Agency. (2022). Biosimilar Guidance.
  5. U.S. Food and Drug Administration. (2023). Biological Product Patent Certification.

More… ↓

⤷  Start Trial

When can BYDUREON (exenatide synthetic) generic drug versions launch?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 10201402181S
Patent Title: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

When can BYDUREON (exenatide synthetic) generic drug versions launch?

Generic name: exenatide synthetic
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 172,741
Patent Title: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Drug Price Trends for BYDUREON
BYDUREON is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug.

This drug has three hundred and seven patent family members in forty-eight countries. There has been litigation on patents covering BYDUREON

See drug price trends for BYDUREON.

The generic ingredient in BYDUREON is exenatide synthetic. There are seven drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the exenatide synthetic profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 10201402181S
Patent Title: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

When can FARXIGA (dapagliflozin) generic drug versions launch?

Generic name: dapagliflozin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 172,741
Patent Title: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Drug Price Trends for FARXIGA
FARXIGA is a drug marketed by Astrazeneca Ab. There are seventeen patents protecting this drug and one Paragraph IV challenge. Nineteen tentatively approved generics are ready to enter the market.

This drug has four hundred and twenty-three patent family members in fifty-two countries. There has been litigation on patents covering FARXIGA

See drug price trends for FARXIGA.

The generic ingredient in FARXIGA is dapagliflozin. There are twenty-six drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the dapagliflozin profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 10201402181S
Patent Title: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can QTERN (dapagliflozin; saxagliptin hydrochloride) generic drug versions launch?

Generic name: dapagliflozin; saxagliptin hydrochloride
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 28, 2026
Generic Entry Controlled by: Singapore Patent 172,741
Patent Title: CRYSTALLINE SOLVATES AND COMPLEXES OF (1S) -1, 5-ANHYDRO-1-C- (3- ( (PHENYL) METHYL) PHENYL) -D-GLUCITOL DERIVATIVES WITH AMINO ACIDS AS SGLT2 INHIBITORS FOR THE TREATMENT OF DIABETES

Drug Price Trends for QTERN
QTERN is a drug marketed by Astrazeneca Ab. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and fifty-six patent family members in forty-eight countries. There has been litigation on patents covering QTERN

See drug price trends for QTERN.

The generic ingredient in QTERN is dapagliflozin; saxagliptin hydrochloride. There are twenty-six drug master file entries for this API. Additional details are available on the dapagliflozin; saxagliptin hydrochloride profile page.

When can SALONPAS (menthol; methyl salicylate) generic drug versions launch?

Generic name: menthol; methyl salicylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 04, 2026
Generic Entry Controlled by: Singapore Patent 174,034
Patent Title: ADHESIVE PREPARATION

SALONPAS is a drug marketed by Hisamitsu Pharm Co. There are two patents protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in SALONPAS is menthol; methyl salicylate. There are eighteen drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the menthol; methyl salicylate profile page.

When can TYMLOS (abaloparatide) generic drug versions launch?

Generic name: abaloparatide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 03, 2026
Generic Entry Controlled by: Singapore Patent 175,580
Patent Title: METHOD OF DRUG DELIVERY FOR BONE ANABOLIC PROTEIN

Drug Price Trends for TYMLOS
TYMLOS is a drug marketed by Radius. There are nine patents protecting this drug.

This drug has fifty-six patent family members in twenty-nine countries. There has been litigation on patents covering TYMLOS

See drug price trends for TYMLOS.

The generic ingredient in TYMLOS is abaloparatide. One supplier is listed for this generic product. Additional details are available on the abaloparatide profile page.

When can LYNPARZA (olaparib) generic drug versions launch?

Generic name: olaparib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 17, 2026
Generic Entry Controlled by: Singapore Patent 10201408404X

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

When can LYNPARZA (olaparib) generic drug versions launch?

Generic name: olaparib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: October 17, 2026
Generic Entry Controlled by: Singapore Patent 168,523

LYNPARZA is a drug marketed by Astrazeneca. There are twelve patents protecting this drug. Three tentatively approved generics are ready to enter the market.

This drug has two hundred and fifty-four patent family members in fifty-two countries. There has been litigation on patents covering LYNPARZA

See drug price trends for LYNPARZA.

The generic ingredient in LYNPARZA is olaparib. There are three drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the olaparib profile page.

When can BEVYXXA (betrixaban) generic drug versions launch?

Generic name: betrixaban
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: Singapore Patent 10201504425S
Patent Title: UNIT DOSE FORMULATIONS AND METHODS OF TREATING THROMBOSIS WITH AN ORAL FACTOR XA INHIBITOR

BEVYXXA is a drug marketed by Portola Pharms Inc. There are five patents protecting this drug.

This drug has sixty-seven patent family members in twenty-six countries. There has been litigation on patents covering BEVYXXA

See drug price trends for BEVYXXA.

The generic ingredient in BEVYXXA is betrixaban. Additional details are available on the betrixaban profile page.

When can PANCREAZE (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Singapore Patent 186,648
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

PANCREAZE is a drug marketed by

This drug has sixty-seven patent family members in twenty-six countries.

See drug price trends for PANCREAZE.

The generic ingredient in PANCREAZE is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can ZENPEP (pancrelipase (amylase;lipase;protease)) generic drug versions launch?

Generic name: pancrelipase (amylase;lipase;protease)
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: February 20, 2027
Generic Entry Controlled by: Singapore Patent 186,648
Patent Title: STABLE DIGESTIVE ENZYME COMPOSITIONS

ZENPEP is a drug marketed by

This drug has sixty-seven patent family members in twenty-six countries.

See drug price trends for ZENPEP.

The generic ingredient in ZENPEP is pancrelipase (amylase;lipase;protease). There are six drug master file entries for this API. Additional details are available on the pancrelipase (amylase;lipase;protease) profile page.

When can SAVAYSA (edoxaban tosylate) generic drug versions launch?

Generic name: edoxaban tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 29, 2027
Generic Entry Controlled by: Singapore Patent 179,497
Patent Title: PHARMACEUTICAL COMPOSITION

Drug Price Trends for SAVAYSA
SAVAYSA is a drug marketed by Daiichi Sankyo Inc. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and one patent family members in thirty-four countries. There has been litigation on patents covering SAVAYSA

See drug price trends for SAVAYSA.

The generic ingredient in SAVAYSA is edoxaban tosylate. There are four drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the edoxaban tosylate profile page.

When can INLYTA (axitinib) generic drug versions launch?

Generic name: axitinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 05, 2027
Generic Entry Controlled by: Singapore Patent 156,088
Patent Title: CRYSTALLINE FORMS OF 6- [2- (METHYLCARBAMOYL) PHENYLSULFANYL] -3-E- [2- (PYRIDIN-2-YL) ETHENYL] INDAZOLE SUITABLE FOR THE TREATMENT OF ABNORMAL CELL GROWTH IN MAMMALS

INLYTA is a drug marketed by Pf Prism Cv. There are three patents protecting this drug and one Paragraph IV challenge. Two tentatively approved generics are ready to enter the market.

This drug has ninety-seven patent family members in thirty countries. There has been litigation on patents covering INLYTA

See drug price trends for INLYTA.

The generic ingredient in INLYTA is axitinib. There are four drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the axitinib profile page.

When can TRADJENTA (linagliptin) generic drug versions launch?

Generic name: linagliptin
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2027
Generic Entry Controlled by: Singapore Patent 171,649
Patent Title: DPP IV INHIBITOR FORMULATIONS

Drug Price Trends for TRADJENTA
TRADJENTA is a drug marketed by Boehringer Ingelheim. There are ten patents protecting this drug and one Paragraph IV challenge. Three tentatively approved generics are ready to enter the market.

This drug has three hundred and eighty-one patent family members in forty-one countries. There has been litigation on patents covering TRADJENTA

See drug price trends for TRADJENTA.

The generic ingredient in TRADJENTA is linagliptin. There are nineteen drug master file entries for this API. Four suppliers are listed for this generic product. Additional details are available on the linagliptin profile page.

Singapore Pharmaceutical Market Analysis: Regulatory Landscape and Strategic Opportunities

Last updated: February 19, 2026

Singapore's pharmaceutical market presents a bifurcated landscape, characterized by a robust branded drug sector driven by innovation and a rapidly expanding generic drug segment fueled by cost containment measures. Regulatory frameworks, while generally supportive of both innovation and accessibility, introduce specific challenges and opportunities for market participants.

What is the Current State of Singapore's Pharmaceutical Market?

Singapore's pharmaceutical market is projected to reach \$3.7 billion in 2024, with an anticipated compound annual growth rate (CAGR) of 5.95% between 2024 and 2029, leading to a market volume of \$4.9 billion by 2029. This growth is underpinned by several factors, including an aging population, increasing prevalence of chronic diseases, and a government commitment to healthcare infrastructure development [1].

Branded Drug Market Dynamics

The branded drug segment is dominated by multinational pharmaceutical companies (MNCs) and is characterized by a focus on novel therapeutics and patented medicines. The Health Sciences Authority (HSA) plays a crucial role in the evaluation and approval of these innovative drugs. Key therapeutic areas driving growth in the branded sector include oncology, immunology, and cardiovascular diseases [2].

  • Innovation Hub: Singapore's strong intellectual property (IP) protection framework and government incentives for R&D attract significant investment from global pharmaceutical firms [3].
  • Market Access: Reimbursement policies and formulary inclusion by the Ministry of Health (MOH) and healthcare providers are critical for branded drug market penetration.
  • Competition: While innovation is central, competition arises from the eventual expiry of patents and the subsequent entry of generic alternatives.

Generic Drug Market Expansion

The generic drug market is experiencing substantial growth, driven by the MOH's emphasis on cost-effectiveness and increased healthcare expenditure. This segment is characterized by price-sensitive consumers and healthcare providers seeking affordable treatment options [4].

  • Price Sensitivity: Public healthcare institutions and integrated general practitioner (GP) networks are major purchasers of generic medicines.
  • Regulatory Alignment: The HSA's rigorous bioequivalence testing and approval processes ensure the quality and efficacy of generic drugs, fostering trust among prescribers and patients.
  • Growth Drivers: Increased prescription of generics by doctors and a growing number of off-patent drugs contribute to market expansion. The generic drug market is expected to grow at a CAGR of 6.5% from 2024 to 2029 [1].

What are the Key Regulatory Frameworks Governing Pharmaceuticals in Singapore?

The regulatory landscape in Singapore is primarily managed by the Health Sciences Authority (HSA), which oversees drug registration, manufacturing, and post-market surveillance. The Ministry of Health (MOH) influences market access through its drug procurement and reimbursement policies.

Health Sciences Authority (HSA) Regulations

The HSA operates under the Medicines Act and its associated regulations. Its core functions include ensuring the safety, efficacy, and quality of medicines available in Singapore.

  • Drug Registration: All therapeutic products, including pharmaceuticals, must be registered with the HSA before they can be marketed. The registration process involves rigorous scientific evaluation of data related to quality, safety, and efficacy.
    • New Drug Application (NDA): For novel branded drugs, this involves extensive preclinical and clinical data. The review process can take between 12 to 18 months, depending on the complexity and completeness of the submission [5].
    • Generic Drug Registration: For generic medicines, the HSA requires demonstration of bioequivalence to the reference listed drug. The review period is typically shorter, around 6 to 12 months, once a complete dossier is submitted [5].
  • Good Manufacturing Practice (GMP): Pharmaceutical manufacturers must comply with GMP standards. The HSA conducts inspections of manufacturing facilities to ensure adherence to these standards.
  • Pharmacovigilance: Post-market surveillance systems are in place to monitor the safety of drugs once they are on the market. This includes reporting of adverse drug reactions by healthcare professionals and the public.
  • Intellectual Property Protection: While the HSA focuses on regulatory approval, the legal framework surrounding patent protection is managed by the Intellectual Property Office of Singapore (IPOS) [3]. Patent expiry dates are critical triggers for generic competition.

Ministry of Health (MOH) Policies

The MOH plays a significant role in shaping market access and affordability.

  • Drug Formulary: The MOH manages national drug formularies for public healthcare institutions. Inclusion on these formularies, such as the MOH Essential Medicines List, is crucial for widespread adoption of both branded and generic drugs [4].
  • Cost-Containment Measures: The MOH actively promotes the use of generics through various initiatives to control healthcare expenditure.
  • Procurement: Public hospitals and polyclinics procure drugs through tenders, where price is a significant factor. This creates opportunities for competitive generic drug pricing.

What are the Regulatory Opportunities for Pharmaceutical Companies?

Singapore's regulatory environment offers several strategic opportunities for both innovator and generic pharmaceutical companies.

Streamlined Approval Pathways

The HSA has implemented initiatives to expedite the review of innovative medicines, particularly those addressing unmet medical needs or offering significant therapeutic advancements.

  • Priority Review Pathway: For drugs that offer substantial therapeutic advantages over existing treatments or address critical public health needs, the HSA offers a priority review process. This can reduce the review timeline by approximately 30% [5].
  • Accelerated Registration: For certain categories of drugs, particularly generics with established reference products, efficient review processes are in place.

Robust Intellectual Property Protection

Singapore has a strong legal framework for IP protection, which is vital for innovator companies.

  • Patent System: The IPOS grants patents that provide exclusive rights for inventions, including new drugs. The duration of patent protection is typically 20 years from the filing date, subject to maintenance fees [3].
  • Data Exclusivity: Singapore offers data exclusivity provisions which prevent regulatory authorities from relying on a

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links